Trotti Andy, Colevas A Dimitrios, Setser Ann, Rusch Valerie, Jaques David, Budach Volker, Langer Corey, Murphy Barbara, Cumberlin Richard, Coleman C Norman, Rubin Philip
H. Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612, USA.
Semin Radiat Oncol. 2003 Jul;13(3):176-81. doi: 10.1016/S1053-4296(03)00031-6.
Multiple systems have been developed for grading the adverse effects (AEs) of cancer treatment. The National Cancer Institute Common Toxicity Criteria (CTC) system has substantially evolved since its inception in 1983. The most recent version, CTCAE v3.0 (Common Terminology Criteria for Adverse Events version 3.0) represents the first comprehensive, multimodality grading system for reporting the acute and late effects of cancer treatment. The new CTC requires changes in the application of AE criteria including new guidelines regarding late effects, surgical and pediatric effects, multimodality issues, and for reporting the duration of an effect. It builds on the strengths of previous systems, represents a considerable effort among hundreds of participants, and signifies an international collaboration and consensus of the oncology research community. This article updates recent progress in the evolution of adverse effects grading systems and reviews the development of CTCAE v3.0.
已经开发了多种系统来对癌症治疗的不良反应(AE)进行分级。自1983年美国国立癌症研究所通用毒性标准(CTC)系统问世以来,它已经有了很大的发展。最新版本CTCAE v3.0(不良事件通用术语标准第3.0版)是首个用于报告癌症治疗急性和晚期效应的全面、多模式分级系统。新的CTC要求在AE标准的应用方面做出改变,包括关于晚期效应、手术和儿科效应、多模式问题以及报告效应持续时间的新指南。它基于先前系统的优势,是数百名参与者共同努力的成果,标志着肿瘤学研究界的国际合作与共识。本文更新了不良反应分级系统演变的最新进展,并对CTCAE v3.0的开发进行了综述。